Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease.

about

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease.

Item

http://www.wikidata.org/entity/Q55506567

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Jak2 Tyrosine Kinase: A Potent ...... diated Cardiovascular Disease.

@en

Jak2 Tyrosine Kinase: A Potent ...... diated Cardiovascular Disease.

@nl

type

Item

label

Jak2 Tyrosine Kinase: A Potent ...... diated Cardiovascular Disease.

@en

Jak2 Tyrosine Kinase: A Potent ...... diated Cardiovascular Disease.

@nl

prefLabel

Jak2 Tyrosine Kinase: A Potent ...... diated Cardiovascular Disease.

@en

Jak2 Tyrosine Kinase: A Potent ...... diated Cardiovascular Disease.

@nl

P1476

Jak2 Tyrosine Kinase: A Potent ...... ediated Cardiovascular Disease

@en

P2093

Annet Kirabo

http://www.w3.org/2001/XMLSchema#string

Peter P. Sayeski

http://www.w3.org/2001/XMLSchema#string

P2860

The Janus kinases (Jaks)

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Fragment-based discovery of JAK-2 inhibitors

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

The conserved box 1 motif of cytokine receptors is required for association with JAK kinases

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

P304

3478-3493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PH3113478

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P932

4034077

http://www.w3.org/2001/XMLSchema#string